Mariner, LLC Halozyme Therapeutics, Inc. Transaction History

Mariner, LLC

$55.8 Billion
Q3 2024

A detailed history of Mariner, LLC transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Mariner, LLC holds 40,516 shares of HALO stock, worth $1.95 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

40,516

Previous 40,843 0.8%

Holding current value

$1.95 Million

Previous $2.14 Million 8.37%

% of portfolio

0.0%

Previous 0.0%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	SELL	$51.3 - $64.42 $16,775 - $21,065	-327 Reduced 0.8%	40,516 $2.32 Million
Q2 2024 Aug 13, 2024	SELL	$37.81 - $52.4 $145,681 - $201,897	-3,853 Reduced 8.62%	40,843 $2.14 Million
Q1 2024 May 15, 2024	SELL	$33.68 - $41.95 $40,584 - $50,549	-1,205 Reduced 2.63%	44,696 $1.82 Million
Q4 2023 Feb 14, 2024	SELL	$33.32 - $42.1 $426,729 - $539,174	-12,807 Reduced 21.81%	45,901 $1.7 Million
Q3 2023 Nov 13, 2023	SELL	$36.46 - $44.03 $514,669 - $621,527	-14,116 Reduced 19.38%	58,708 $2.24 Million
Q2 2023 Aug 11, 2023	SELL	$30.28 - $38.74 $173,716 - $222,251	-5,737 Reduced 7.3%	72,824 $2.63 Million
Q1 2023 May 12, 2023	SELL	$32.86 - $55.7 $111,526 - $189,045	-3,394 Reduced 4.14%	78,561 $3 Million
Q4 2022 Feb 14, 2023	SELL	$40.06 - $59.44 $60,210 - $89,338	-1,503 Reduced 1.8%	81,955 $4.66 Million
Q3 2022 Nov 10, 2022	BUY	$38.53 - $51.78 $2.8 Million - $3.77 Million	72,762 Added 680.27%	83,458 $3.3 Million
Q2 2022 Aug 15, 2022	BUY	$37.35 - $48.3 $399,495 - $516,616	10,696 New	10,696 $471,000

Others Institutions Holding HALO

# of Institutions

544

Shares Held

126M

Call Options Held

294K

Put Options Held

180K

View Full List

About HALOZYME THERAPEUTICS, INC.

Ticker HALO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 139,288,992
Market Cap $6.69B
Description
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...

More about HALO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Mariner, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Mariner, LLC with notifications on news.

Account